about
Forecasts of health care utilization related to pandemic A(H1N1)2009 influenza in the Nord-Pas-de-Calais region, France.Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis.Prevalence and underdiagnosis of airway obstruction among middle-aged adults in northern France: The ELISABET study 2011-2013.Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.Both exhaled nitric oxide and blood eosinophil count were associated with mild allergic asthma only in non-smokers.Factors associated with the 6-minute walk distance in patients with systemic sclerosis.Low-grade systemic inflammation: a partial mediator of the relationship between diabetes and lung function.Changes over time in the prevalence and treatment of cardiovascular risk factors, and contributions to time trends in coronary mortality over 25 years in the Lille urban area (northern France).Global Lung Function Initiative reference equations better describe a middle-aged, healthy French population than the European Community for Steel and Coal values.Altered B lymphocyte homeostasis and functions in systemic sclerosis.Sources of household air pollution: The association with lung function and respiratory symptoms in middle-aged adult.Whole-Body Distribution and Clinical Association of Telangiectases in Systemic SclerosisShort-term exposure to air pollution: Associations with lung function and inflammatory markers in non-smoking, healthy adultsAssociations between long-term exposure to air pollution, glycosylated hemoglobin, fasting blood glucose and diabetes mellitus in northern FranceExhaled breath NOx levels in a middle-aged adults population-based study: reference values and association with the smoking statusValidation of a Short, Qualitative Food Frequency Questionnaire in French Adults Participating in the MONA LISA-NUT Study 2005-2007Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-AnalysisSurvival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literatureHow can screening for malnutrition among hospitalized patients be improved? An automatic e-mail alert system when admitting previously malnourished patientsResidential exposure to outdoor air pollution and adult lung function, with focus on small airway obstructionSerious infectious events and immunoglobulin replacement therapy in patients with autoimmune diseases receiving rituximab: a retrospective cohort studyEvaluation of efficacy and tolerability of first-line therapies in NMOSDFine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014)Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in FranceEffectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohortSwitching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort studyPhenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic SclerosisReply
P50
Q30204543-DEB99168-ECA2-42B1-BB30-A20A4C3F8EC7Q36245534-4AA12FBA-EBD8-4E5F-BA0C-0808089345D0Q40326071-FE205ACC-765E-4439-8596-07C19D59E0A6Q40491053-EBF0A5EE-A55A-488F-8049-C86B711FAF1DQ41145826-C03E9993-7140-4D44-98CA-7E901062AB19Q47151670-F82C34CC-0338-42E9-9704-F3A881AAA8FDQ47312225-42613413-5184-4024-A43A-A10308454750Q47668121-A9B23840-1D41-4D55-9CD0-C4AFC00392BAQ48104789-A250D684-0207-4422-9113-3500C71DFE77Q49990679-6E6B9691-4300-432A-BE3A-BC72471FD669Q51766895-DA0DD045-5AD3-47E9-82C5-355354FC201BQ56977476-C74F9FC4-09E8-46D0-A3AA-B5EAF48D99E5Q57479970-5D4C7BC3-F938-4428-BD0E-5FB68AAB64A9Q57605560-C3D722C4-DE85-4723-B060-25E74FD677FDQ57605583-B22ADC60-69EE-4CCD-B25D-E9616281354BQ57658231-AE99F3DD-20B7-4F42-B8FC-410BD5812B5EQ59125590-DBD956AD-6945-4FCC-A9AA-65D580196BA0Q64078682-83BCC27E-4B0B-4553-AC4F-F2B1089742B8Q85668986-D85C0165-B96C-45F0-9C87-8359C99A613FQ89446359-C7144181-E2AA-4CC8-9C00-7F07CAB8A40DQ89749018-4575B843-FA0F-4362-B098-2268FA4792FBQ90316227-BE8247B3-0BC7-4A90-9440-D7685C3E758CQ90541976-62B848EF-EE91-4606-A979-7042056A2B7CQ91396932-5D870AF5-F1AD-4B5A-84D7-C73199A657D3Q92068258-5AAF2BAC-FCC9-45D4-82E3-10C2953DC53BQ92457897-BAE5CDF9-C8AE-4DCA-A6BA-70AD2D612A12Q92996385-EAB1E084-CE11-4BF7-820F-84E2F775CDF1Q95553742-0512DA13-7B61-4B4D-954E-1598EF694D84
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan Giovannelli
@ast
Jonathan Giovannelli
@en
Jonathan Giovannelli
@es
Jonathan Giovannelli
@nl
type
label
Jonathan Giovannelli
@ast
Jonathan Giovannelli
@en
Jonathan Giovannelli
@es
Jonathan Giovannelli
@nl
prefLabel
Jonathan Giovannelli
@ast
Jonathan Giovannelli
@en
Jonathan Giovannelli
@es
Jonathan Giovannelli
@nl
P106
P1153
55863690400
P21
P31
P496
0000-0002-7516-4670